2024
Epidemiology and risk factors for hyperkalaemia in heart failure
Grobbee D, Filippatos G, Desai N, Coats A, Pinto F, Rosano G, Cleland J, Kammerer J, de Arellano A. Epidemiology and risk factors for hyperkalaemia in heart failure. ESC Heart Failure 2024, 11: 1821-1840. PMID: 38439165, PMCID: PMC11287317, DOI: 10.1002/ehf2.14661.Peer-Reviewed Original ResearchHeart failureObservational studyRisk factorsRenin-angiotensin-aldosterone system inhibitorsSevere renal impairmentElevated serum potassiumImpaired renal functionRisk of hyperkalaemiaIncreased risk of mortalityAdverse cardiovascular eventsClinical epidemiological dataFollow-up lengthChronic kidney diseaseRisk of mortalityIdentified risk factorsMild hyperkalaemiaPotassium bindersRenal impairmentConcomitant medicationsHF therapyDiagnosed HFRenal functionSerum potassiumClinical careClinical outcomes
2023
Patterns of Care and Outcomes of Ambulatory Endovascular Interventions in Lower Extremity Peripheral Arterial Disease
Chaturvedi A, Castro-Dominguez Y, Gertz Z, Lawson B, Chandrika P, Gupta R, Milioglou I, Sung J, Desai N, Vetrovec G, Kochar A, Guha A. Patterns of Care and Outcomes of Ambulatory Endovascular Interventions in Lower Extremity Peripheral Arterial Disease. The American Journal Of Cardiology 2023, 194: 17-26. PMID: 36924641, DOI: 10.1016/j.amjcard.2023.02.006.Peer-Reviewed Original ResearchConceptsPatterns of careEndovascular interventionCardiovascular eventsLower Extremity Peripheral Arterial DiseaseLower extremity endovascular interventionsChronic kidney diseasePeripheral arterial diseasePeripheral artery diseasePrimary treatment modalityIschemic heart diseaseNon-Medicare insuranceUrban teaching facilityDisease refractoryUncontrolled hypertensionMost patientsArtery diseaseHeart failureArterial diseaseStudy cohortKidney diseaseMean ageNoninvasive managementTreatment modalitiesHeart diseaseFemale gender
2020
Baseline and on-treatment serum bicarbonate, intensive blood pressure lowering, and mortality: the Systolic Blood Pressure Intervention Trial (SPRINT)
Pareek M, Byrne C, Vaduganathan M, Biering-Sorensen T, Krogager M, Kragholm K, McCullough M, Desai N, Olsen M, Bhatt D. Baseline and on-treatment serum bicarbonate, intensive blood pressure lowering, and mortality: the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal 2020, 41: ehaa946.2731. DOI: 10.1093/ehjci/ehaa946.2731.Peer-Reviewed Original ResearchSystolic Blood Pressure Intervention TrialIntensive blood pressureSerum bicarbonate levelsBlood pressureBaseline bicarbonateBicarbonate levelsCV causesAntihypertensive treatmentSystolic blood pressure 130End-stage renal diseaseStandard antihypertensive treatmentHigh cardiovascular riskChronic kidney diseaseGlomerular filtration rateRisk of deathStandard blood pressureLow bicarbonate levelsYears of ageMultivariable adjustmentCardiovascular riskSerum bicarbonateRenal diseaseLaboratory variablesPrognostic implicationsIntervention trials